louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01833247: Lactic Acidosis During and After Seizures
Official title: Lactic Acidosis During and After Seizures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: epilepsy
lactic acid
saliva
postictal
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2013-04-16
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age range will be 18-75, men and women, all ethnic backgrounds to be eligible. Eligible population will be determined by who gets admitted to the epilepsy monitoring unit with a history of generalized tonic-clonic seizures.

Brief summary: This project looks at the time course of lactic acid rise (if any) after seizures. Salivary and capillary lactic acid are tested. This type of measurement may be useful in signalling the occurrence or recent history of a seizure.

Detailed description: Lactic acid is released from cells during seizures and elevates lactic acid levels in blood and saliva. The time course of this rise is unknown. If lactic acid rises within a few minutes of a seizure, than it might be feasible to develop lactic acid sensors to provide notification of a recent seizure. This could lead to better safety monitoring for people with epilepsy. This study was designed to utilize a commercially available lactic acid sensor (investigators have no connection with the sensor manufacturer and purchased the device at list price) to measure salivary lactic acid levels after a seizure during inpatient video-EEG epilepsy monitoring.

Eligibility criteria: Inclusion Criteria:

1. Age 18-75 inclusive.
2. History of at least one generalized tonic-clonic (grand mal) seizure prior to enrollment in the study.
3. Undergoing monitoring in the Stanford Epilepsy Monitoring Unit.

   Exclusion Criteria:
4. Not pregnant.
5. Inability to understand and sign the consent form.
6. No known history of mitochondrial disease or other metabolic disorders expected to affect blood lactate.
7. No known history of thrombophlebitis or excessive tendency to bleeding. Not on coumadin. Aspirin or anti-platelet agents are not an exclusion.
8. No known peripheral vascular disease affecting blood circulation to the fingers.
9. No painful peripheral neuropathy.
10. No Raynaud's disease or phenomenon.

Primary outcomes:
measure: Salivary Lactic Acid Levels With Seizures
timeFrame: Within 10 minutes of end of the seizure
measure: Capillary Lactic Acid Levels With Seizures
timeFrame: Within 10 minutes of end of the seizure
measure: Intravenous Lactic Acid Levels With Seizures
timeFrame: Within 10 minutes of end of the seizure
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Hospital
state: California
Study officials:
affiliation: Stanford University Department of Neurology
name: Robert S Fisher, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01279447: Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control
Official title: Infrapatellar Nerve Block for Post-operative Analgesia for Knee Arthroscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Internal Derangement of Knee
Keywords: infrapatellar nerve
saphenous nerve
knee arthroscopy
nerve block
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2011-01-19
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy.

Detailed description: The purpose of this study is to determine whether infrapatellar branch of the saphenous nerve blocks are effective in decreasing analgesic use, promoting earlier mobility, and improving long term outcome scores after knee arthroscopy. Randomized, double-blinded, placebo controlled, study.

Eligibility criteria: Inclusion Criteria:

* planned knee arthroscopy with soft tissue intervention
* age 18+
* English speaking

Exclusion Criteria:

* contraindications to nerve block: eg neuropathy, type 1 diabetes, coagulopathy
* knee arthroscopy with planned bony intervention

Primary outcomes:
measure: Post op Pain Score
timeFrame: 0 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Olson Surgical Pavilion
state: Illinois
Study officials:
affiliation: Northwestern University
name: Gordon Nuber, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Northwestern University
name: Antoun Nader, MD
role: STUDY_DIRECTOR
affiliation: Northwestern University
name: Lawrence Hsu, MD
role: STUDY_DIRECTOR
affiliation: Northwestern University
name: Mark Kendall, MD
role: STUDY_DIRECTOR
References:
citation: Akkaya T, Ersan O, Ozkan D, Sahiner Y, Akin M, Gumus H, Ates Y. Saphenous nerve block is an effective regional technique for post-menisectomy pain. Knee Surg Sports Traumatol Arthrosc. 2008 Sep;16(9):855-8. doi: 10.1007/s00167-008-0572-4. Epub 2008 Jun 24.
citation: Lundblad M, Kapral S, Marhofer P, Lonnqvist PA. Ultrasound-guided infrapatellar nerve block in human volunteers: description of a novel technique. Br J Anaesth. 2006 Nov;97(5):710-4. doi: 10.1093/bja/ael241. Epub 2006 Sep 26.
citation: Arthornthurasook A, Gaew-Im K. Study of the infrapatellar nerve. Am J Sports Med. 1988 Jan-Feb;16(1):57-9. doi: 10.1177/036354658801600110.
Clinical trial NCT00430547: Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
Official title: Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Graves' Ophthalmopathy
Lead sponsor: Barwon Health
Sponsor class: OTHER_GOV
Collaborators: name: University of Melbourne
name: National Health and Medical Research Council, Australia
First posted: 2007-02-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.


Eligibility criteria: Inclusion Criteria:

* Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion Criteria:

* Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
* Age \< 18 years
* Inability to consent to participation in the study
* Pregnancy
* History of radio-active iodine therapy

Primary outcomes:
measure: Onset or progression of ophthalmopathy following radio-active iodine therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Geelong
country: Australia
facility: Barwon Health - The Geelong Hospital
state: Victoria
Study officials:
affiliation: University of Sydney
name: Jack R Wall, BMBS, FRACP, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01733147: Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
Official title: Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Barrett's Esophagus
Obesity
Keywords: Omega-3 fatty acid
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-11-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.


Eligibility criteria: Inclusion Criteria

* Presence of BE defined as ≥ 1 cm of visible columnar mucosa in the distal esophagus with intestinal metaplasia on histology.
* Absence of high grade dysplasia or EAC on baseline histology.
* BMI \> 30 kg/m2 or waist circumference \> 102 cm in men, \> 88 cm in women.
* Ability to give informed consent.

Exclusion Criteria

* Allergy to ω3 FFAs, fish or shellfish.
* Presence of high grade dysplasia or cancer on histology.
* Pregnant and or breastfeeding women
* Presence of esophagitis on initial endoscopy or symptoms of refractory GERD (heartburn or regurgitation ≥ 2 times a week) indicative of uncontrolled gastroesophageal reflux.
* Inability to give informed consent.
* Currently taking Omega3 FFA as prescription.
* Anti-coagulant therapy (Plavix, Warfarin, Coumadin)
* AST or ALT level \> three times upper limit of normal at baseline
* LDL \> 200 mg/dl at baseline.
* INR \> 2

Primary outcomes:
measure: Change in Serum PGE2 Levels
timeFrame: Baseline, 6 months
measure: Change in Esophageal Tissue PGE2 Levels
timeFrame: Baseline, 6 months
Secondary outcomes:
measure: Change in Esophageal Macrophage Markers
timeFrame: Baseline, 6 months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Prasad Iyer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00885547: Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
Official title: Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: IgA Nephropathy
Lead sponsor: Nanjing University School of Medicine
Sponsor class: OTHER
First posted: 2009-04-22
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to:

1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis.
2. To evaluate the safety and tolerability of TW.

Detailed description: Patients who fit the inclusion criteria will be randomly divided into three groups: TW group (TW at dosage of 90 mg/d), ARB group (the control group, valsartan at dosage of 160 mg/d) and combined treatment group (TW at dosage of 60 mg/d and valsartan at dosage of 80 mg/d).

Eligibility criteria: Inclusion Criteria:

1. 18-60 years old but no requirement for gender
2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic abnormal urinalysis
3. Informed consent is obtained from each research subject who agrees to conduct a periodic follow-up according to the research arrangement

Exclusion Criteria:

1. Secondary IgA nephropathy, such as Henoch-Schönlein purpura nephritis, Lupus nephritis and so on
2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis
3. Severe infection
4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or glutamic-oxal(o)acetic transaminase (GOT) more than twice upper limit of normal
5. Women during pregnancy and lactation
6. Patients need to procreation lately
7. Patients treated with TW or ARB within 4 months

Primary outcomes:
measure: The percentage got to complete remission (CR) of TW group, the combined treatment group, and the control group after the 3, 6 months treatment.
timeFrame: 12 months
Secondary outcomes:
measure: The percentage of total effect of the 3 groups and adverse event within the follow-up periods.
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Nanjing University School of Medicine
name: Zheng Tang, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01955447: Post-prandial Glucose in Healthy Subjects
Official title: Effect of Different Levels of Plant-based Ingredients on Post-prandial Glucose in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Keywords: Blood glucose
Lead sponsor: Unilever R&D
Sponsor class: INDUSTRY
First posted: 2013-10-07
Enrollment: 84
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study is designed to determine the extent to which foods containing different levels of plant-based ingredients affect blood glucose responses in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Willing to give consent to participate in the study in writing;
* Healthy male and female subjects, between the age of ≥20 and ≤50 yrs of age at first screening visit;
* Body Mass Index (BMI) between ≥18 and ≤ 25 kg/m2;
* Apparently healthy: no medical conditions which might affect study measurement, as judged by study physician and/or measured by questionnaire, and/or assessed by haematology, blood chemistry and urinalysis;
* Willing to comply to study protocol during the study;
* Agreeing to be informed about medically relevant personal test-results by study physician;
* Willing to refrain from drinking of alcohol on and one day before the blood withdrawal;
* Fasting blood glucose value of volunteer is ≥ 3.4 and ≤ 6.1 mmol/litre (i.e. 62-110 mg/dl) at screening;
* Haemoglobin level within clinically acceptable range (for male 12 to 17 gm/dL and for females 11 to 15 gm / dL; both inclusive) as judged by the research physician.

Exclusion Criteria:

* Being an employee of Unilever or CRO;
* Chronic smokers, tobacco chewers and drinkers;
* Participation in any other biomedical study 3 months before screening visit day of this study and/or participating in any other biomedical study during the screening period;
* Use of medication which interferes with study measurements including vitamins, tonics;
* Reported intense exercise ≥10 h/week;
* Reported weight loss/gain ≥ 10% of body weight in the 6 months preceding screening
* Blood donation for 2 months prior to screening;
* Urine analysis that showed any drug abuse;
* Allergy to any food or cosmetics;
* If female, not being pregnant or planning pregnancy during the study period;
* If female, lactating or has been lactating for 6 weeks before pre-study investigation and/or during the study period.

Primary outcomes:
measure: Post-prandial blood glucose area under the curve
timeFrame: 120 minutes
Secondary outcomes:
measure: Post-prandial insulin area under the curve
timeFrame: 120 minutes
Other outcomes:
Locations:
city: Ahmedabad
country: India
facility: Lambda Therapeutics Research Ltd (LTRL)
Study officials:
affiliation: Lambda Therapeutics Research Ltd (LTRL)
name: Dr Ketul Modi, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02439047: Preliminary Study to the Manufacturing of a Non-stick Membrane for Surgery Using Patient's Own Cells (MESO-PATCH)
Official title: Non-stick Patch of Mesothelial Cells in a Hydrogel Matrix : Exploratory Analysis Assessing the Morphotype and Mesothelial Phenotype After Culture From 2 Cells Sources of Human Origin.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cancer
Keywords: reconstructive surgery
abdominal surgery
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2015-05-08
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of this study, which will be realised in vitro on human samples, is to test 2 cell sources isolated from peritoneum for adult mesothelial cells (peritoneal samples) and from adipose tissue for the adipose stem cells (adipose tissue samples). The latter will be differentiated towards the mesothelial phenotype and morphotype. The 2 routes will be compared and the most satisfactory one will be chosen to make a non-stick patch.

Detailed description: * Patient information and collection of a signed informed consent
* Clinical data collection: surgery date, age, weight, height, medical and surgical history
* Prospective collection of peritoneal and adipose biopsies of patients during their surgery at the Oscar Lambret Center (Dr L. BRESSON)
* Transportation of the samples to the 1008 INSERM Unit.
* Isolation of cells from the samples : mesothelial cells from the peritoneum and adipose stem cells from adipose tissue
* Cell culture and expansion of mesothelial cells; and cell culture and differentiation of adipose stem cells
* Identification by the morphotype and phenotype of mesothelial cells
* Comparison of the results according to the cell source, peritoneum or adipocyte, to the purity of cells and to the efficacy of the expansion

Eligibility criteria: Inclusion Criteria:

* Aged more than 18 years old,
* Planned surgery For peritoneal samples : abdominal surgery (laparotomy or coelioscopy) For adipose tissue samples : breast reconstructive surgery (lipomodelage)
* Informed and signed consent

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Patient under guardianship or tutorship
* For peritoneal samples : previous abdomino-pelvic radiotherapy or abdominal surgery ; peritoneal carcinosis

Primary outcomes:
measure: Morphotype/Phenotype expression
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
Study officials:
affiliation: Centre Oscar Lambret
name: Lucie BRESSON, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: INSERM U1008
name: Feng Chai, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03497247: Mindfulness-Based Cognitive-Behavioral Therapy for Gambling Disorder
Official title: Mindfulness-Based Cognitive-Behavioral Therapy for Gambling Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gambling Disorder
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Spanish Clinical Research Network - SCReN
First posted: 2018-04-13
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare two group psychological interventions for Gambling Disorder in terms of effectiveness and efficacy. One group is based in cognitive-behavioral therapy (TAU) and the other group is based in TAU with Mindfulness-Based Relapse Prevention (Chawla, Marlatt \& Gordon, 2011). Both interventions are composed by 14 weekly sessions, and follow-up to a month, three months, six months, one and two years.


Eligibility criteria: Inclusion Criteria:

* Gambling Disorder (DSM-5; APA, 2013).
* 18 years or older.
* Males and females.

Exclusion Criteria:

* Current psychosis or other severe/acute mental disorder.
* Current substance abuse.
* Intellectual disability.
* Under 18 years.

Primary outcomes:
measure: South Oaks Gambling Screen (SOGS; Lesieur and Blume, 1987)
timeFrame: 5 minuts
measure: DSM-IV-TR (APA 2000)
timeFrame: 5 minuts
measure: Difficulties in Emotion Regulation Scale (DERS, Gratz and Roemer, 2004)
timeFrame: 5 minuts
measure: Five Facets Mindfulness Questionnaire (FFMQ; Baer et al. 2006)
timeFrame: 5 minuts
measure: EQ-Decentering (Soler et al., 2014)
timeFrame: 5 minuts
measure: Gambling Related Cognitions Scale (GRCS; Raylu & Oei, 2004)
timeFrame: 5 minuts
measure: MBRP - Adherence and Competence Scale (Chawla et al. 2010
timeFrame: 90 minuts (by co-therapist)
Secondary outcomes:
measure: Temperament and Character Inventory-Revised (TCI-R; Cloninger 1999)
timeFrame: 20 minuts
measure: Symptom Checklist-Revised (SCL-90-R; Derogatis 1990)
timeFrame: 20 minuts
measure: UPPS (Whiteside and Lynam, 2001)
timeFrame: 10 minuts
measure: URICA - problem gambling (Gómez-Peña et al. 2011)
timeFrame: 10 minuts
measure: AUDIT (OMS, 1989)
timeFrame: 5 minuts
measure: DUDIT (Berman et al. 2003)
timeFrame: 5 minuts
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Santa Creu i Sant Pau Hospital
Study officials:
affiliation: Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau
name: Marta Sancho, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04756947: Pediatric Pelvic Injuries - Epidemiology and Demography
Official title: Epidemiological Study of Pediatric Pelvic Injuries
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvis Injury
Child, Only
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
Collaborators: name: Faculty Hospital Kralovske Vinohrady
name: University Hospital Pilsen
First posted: 2021-02-16
Enrollment: 358
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 358 patients (243 boys, 115 girls), mean age (SD) 14.1 ± 3.0 years

Brief summary: A retrospective epidemiological study of pediatric pelvic injury from level 1 trauma centre.

Hypothesis: In the pediatric population, majority of pelvic injuries is of type A according to AO/OTA (Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association) classification, the treatment is mostly conservative and complications of injury and treatment are less common than in adults.

Detailed description: Study design: Retrospective analysis (13 years), excluding pathological fractures. AO/OTA type, epidemiological data, mode of treatment, and complications were recorded. Data were analyzed using the Fisher exact test and the Wilcoxon test.

Eligibility criteria: Inclusion Criteria of primary study group:

* Age ≤ 18 years
* Single pelvic bone fractures or pelvic ring injuries

Inclusion Criteria of secondary study group:

* Age ≤ 18 years
* Combined pelvic and acetabular injuries
* Isolated fractures of the acetabulum

Exclusion Criteria:

* Pathological fractures

Primary outcomes:
measure: Epidemiological study of pediatric pelvic trauma
timeFrame: Follow-up of each patient for minimum 12 months.
Secondary outcomes:
measure: Demographical study of pediatric pelvic trauma
timeFrame: Follow-up of each patient for longer then 12 months.
Other outcomes:
Locations:
Study officials:
affiliation: Charles University, Czech Republic
name: Valer Dzupa, MD
role: STUDY_CHAIR
References:
citation: DeFrancesco CJ, Sankar WN. Traumatic pelvic fractures in children and adolescents. Semin Pediatr Surg. 2017 Feb;26(1):27-35. doi: 10.1053/j.sempedsurg.2017.01.006. Epub 2017 Jan 5.
citation: Tosounidis TH, Sheikh H, Giannoudis PV. Pelvic Fractures in Paediatric Polytrauma Patients: Classification, Concomitant Injuries and Early Mortality. Open Orthop J. 2015 Jul 31;9:303-12. doi: 10.2174/1874325001509010303. eCollection 2015.